Repligen Financial Ratios
NASDAQ: RGENHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Repligen ratio analysis
Repligen earned a net margin of 6.6% in FY 2025, up from -4.0% a year earlier. Gross margin was 52.3% compared with a median of 55.4% over the prior 9 years. Return on equity reached 2.3%, meaning Repligen generated 0.02 dollars of profit for every dollar of shareholders' equity.
Debt-to-equity stood at 0.26 versus 0.27 the year before, and the current ratio was 8.37. At the end of FY 2025, RGEN traded at 191.1 times earnings; across the 9 fiscal years shown, its year-end P/E ranged from 50.4 to 285.4, with a median of 137.5. Valuation ratios use the closing share price on each fiscal year-end date and diluted shares from the income statement; profitability and leverage ratios use reported annual figures. Current valuation multiples are on the statistics page.
Summary generated from market data by MetaCap's automated system. Methodology
Repligen financial ratios (annual)
| Ratio | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| P/E ratio (at fiscal year end) | 191.10 | — | 285.40 | 52.26 | 118.23 | 172.64 | 210.77 | 137.46 | 50.39 | 90.65 |
| Price / sales | 0.01 | 0.01 | 0.02 | 0.01 | 0.02 | 0.03 | 16.59 | 11.47 | 9.82 | 0.01 |
| Price / book | 0.00 | 0.00 | 0.01 | 0.00 | 0.01 | 0.01 | 4.23 | 3.62 | 2.34 | 0.01 |
| Gross margin | 52.3% | 43.3% | 44.0% | 56.9% | 58.3% | 57.2% | 55.9% | 55.4% | 52.5% | 54.9% |
| Operating margin | 7.5% | -5.5% | 7.5% | 28.0% | 24.9% | 19.1% | 13.4% | 13.4% | 9.9% | 15.3% |
| Net margin | 6.6% | -4.0% | 5.6% | 23.2% | 19.1% | 16.4% | 7.9% | 8.6% | 20.1% | 11.2% |
| Free cash flow margin | 12.7% | 23.6% | 12.3% | 10.9% | 7.7% | 11.0% | 18.0% | 11.4% | 8.5% | 3.1% |
| Return on equity (ROE) | 2.3% | -1.3% | 1.8% | 9.7% | 7.3% | 3.9% | 2.0% | 2.7% | 4.8% | 6.9% |
| Return on assets (ROA) | 1.7% | -0.9% | 1.3% | 7.3% | 5.4% | 3.1% | 1.5% | 2.1% | 3.8% | 4.0% |
| Debt / equity | 0.26 | 0.27 | — | — | — | — | — | — | — | — |
| Current ratio | 8.37 | 8.41 | 6.74 | 2.47 | 2.48 | 2.83 | 13.28 | 2.12 | 9.63 | 8.74 |
| Revenue growth | 16.4% | 0.3% | -21.1% | 19.5% | 83.1% | 35.5% | 39.3% | 37.4% | 35.1% | 25.1% |
| EPS growth | — | -173.0% | -80.6% | 44.6% | 101.8% | 152.3% | 18.9% | -48.6% | 111.8% | 21.4% |